NCT01686256 is a Phase 1 clinical trial of Tc 99m EC20 in Ovarian Cancer, sponsored by Endocyte.

Who is sponsoring NCT01686256?

NCT01686256 is sponsored by Endocyte.

What drugs are being tested in NCT01686256?

Interventions in NCT01686256: Tc 99m EC20.

What condition does NCT01686256 study?

NCT01686256 studies Ovarian Cancer, Endometrial Cancer.

Is NCT01686256 still recruiting?

NCT01686256 is currently completed. Last updated 20 June 2023.

Last reviewed 2023-06-20 · How we verify

NCT01686256

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

A Multi-center Clinical Study to Evaluate the Safety and Efficacy of FolateScan (Technetium Tc 99m EC20) in Women With Suspected Ovarian or Endometrial Cancer

Completed Phase 1 Last updated 20 June 2023

What this trial tests

Phase 1 trial testing Tc 99m EC20 in Ovarian Cancer in 12 participants. Completed.

Timeline

1 August 2001

Primary endpoint
1 August 2004

Quick facts

Lead sponsor	Endocyte
Phase	Phase 1
Status	Completed
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	other
Enrollment	12
Start date	1 August 2001
Primary completion	1 August 2004
Sites	1 location across United States

Drugs / interventions tested

Tc 99m EC20 — full drug profile →

Conditions studied

Ovarian Cancer — all drugs for Ovarian Cancer →
Endometrial Cancer — all drugs for Endometrial Cancer →

Sponsor

Endocyte — full company profile →

Who can join

18 and older, female only, with Ovarian Cancer or Endometrial Cancer. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

A Multi-Center Clinical Study to Evaluate the Safety and Efficacy of FolateScan (Technetium Tc 99m EC20) in Women with Suspected Ovarian or Endometrial Cancer. Phase I - The proposed indication for FolateScan is disease or pathological assessment of ovarian or endometrial masses.

Publications & conference data

2 peer-reviewed publications reference this trial (live from Europe PMC):

Targeting folate receptor alpha for cancer treatment.
Cheung A, Bax HJ, Josephs DH, Ilieva KM, et al · · 2016 · cited 298× · PMID 27248175 · DOI 10.18632/oncotarget.9651
Single- versus Dual-Targeted Nanoparticles with Folic Acid and Biotin for Anticancer Drug Delivery.
Jurczyk M, Jelonek K, Musiał-Kulik M, Beberok A, et al · · 2021 · cited 71× · PMID 33802531 · DOI 10.3390/pharmaceutics13030326

Verify or expand the search:

Other recruiting trials for Ovarian Cancer

Currently open trials in the same condition.

NCT06412120 — Study Evaluating Safety, Tolerability, and Metabolism of Niraparib · Phase 4 · recruiting
NCT06930755 — Study of NMS-03305293 in Adult Patients With Relapsed Ovarian Cancer · Phase 1 · recruiting
NCT07318558 — A Clinical Trial of Sac-TMT in People With Non-HRD Positive Advanced Ovarian Cancer (MK-2870-021) · Phase 3 · recruiting
NCT07491081 — EARLY Study: Evaluating the Specificity and Feasibility of the EARLY Biomarker Panel for Ovarian Cancer Detection · NA · recruiting
NCT07410676 — EBNK-001 Allogeneic NK Cells With Low-Dose IL-15 ± Pembrolizumab in Advanced Solid Tumors · Phase 1, PHASE2 · recruiting

Other Endocyte trials

Trials by the same sponsor.

NCT04597411 — Study of 225Ac-PSMA-617 in Men With PSMA-positive Prostate Cancer · Phase 1 · recruiting
NCT03511664 — Study of 177Lu-PSMA-617 In Metastatic Castrate-Resistant Prostate Cancer · Phase 3 · completed
NCT03042312 — Lutetium-177 (Lu177) Prostate-Specific Antigen (PSMA)-Directed EndoRadiotherapy · Phase 2 · terminated
NCT03011320 — An Exploratory Study of the Folic Acid-tubulysin Conjugate EC1456 in Ovarian Cancer Subjects Undergoing Surgery · Phase 1 · completed
NCT01170650 — Study for Women With Platinum Resistant Ovarian Cancer Evaluating EC145 in Combination With Doxil® (PROCEED) · Phase 3 · terminated

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT01686256 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Endocyte
Last refreshed: 20 June 2023

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT01686256.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing